Clinical Trials Browser

Phase 2 × pertuzumab × Gastrointestinal × Clear all

NCT03365882 2026-02-10

S1613, Trastuzumab and Pertuzumab or Cetuximab and Irinotecan Hydrochloride in Treating Patients With Locally Advanced or Metastatic HER2/Neu Amplified Colorectal Cancer That Cannot Be Removed by Surgery

Phase 2 Completed

240 enrolled 14 charts

Gastrointestinal

Colonic Neoplasms, Rectal Neoplasms

NCT07129018 2025-08-19

Trastuzumab Rezetecan Combined With Pertuzumab and Iparomlimab and Tuvonralimab for Biliary Tract Cancer

Phase 2 Not yet recruiting

Gastrointestinal

Biliary Tract Neoplasms

NCT02205047 2025-07-31

INNOVATION

Phase 2 Completed

Gastrointestinal

Stomach Neoplasms

NCT02091141 2024-07-23

My Pathway: A Study Evaluating Herceptin/Perjeta, Tarceva, Zelboraf/Cotellic, Erivedge, Alecensa, and Tecentriq Treatment Targeted Against Certain Molecular Alterations in Participants With Advanced Solid Tumors

Phase 2 Completed

673 enrolled 22 charts

GastrointestinalGenitourinary

Biliary Tract Neoplasms, Urinary Bladder Neoplasms, Neoplasms

NCT04591431 2023-10-03

ROME

Phase 2 Unknown

BreastGastrointestinalThoracic

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Gastrointestinal Neoplasms

NCT03225937 2018-10-30

HERACLES

Phase 2 Unknown

Gastrointestinal

Colorectal Neoplasms

NCT01461057 2018-08-09

JOSHUA

Phase 2 Completed

30 enrolled 9 charts

Gastrointestinal

Stomach Neoplasms

NCT01108458 2017-03-03

A Phase 2 Study of Pertuzumab and Erlotinib for Refractory Pancreatic Adenocarcinoma

Phase 2 Terminated

1 enrolled 4 charts

Gastrointestinal

Pancreatic Neoplasms